Opinion|Videos|August 28, 2024
Spectrum of Hypercortisolism Presentations
Key opinion leaders explore the diverse clinical manifestations of hypercortisolism across its spectrum of presentations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you discuss the spectrum of hypercortisolism and its various clinical presentations, especially in T2D?
- Based on the prevalence data from the CATALYST study, how should we approach screening of patients for hypercortisolism?
- Are there specific subgroups of patients with T2D who may have a higher prevalence of hypercortisolism?
- Can you talk about testing for hypercortisolism? What tests are recommended for screening and subsequent confirmation?
- Can you explain the dexamethasone suppression test (DST) used in the CATALYST study?
Advertisement
Related to this article
In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.
Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.
At GOLD 2026, Alvar Agustí, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
In the phase 2b VISTAS trial, volixibat improved sleep vs placebo in PSC with cholestatic pruritus, and itch responders saw greater fatigue and sleep gains.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
Conference Preview: 2026 GOLD International COPD Conference
3
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5